Richard Frisbee Memorial Lecture

Markus Müschen, MD, PhD
Arthur H. and Isabel Bunker Professor of Medicine (Hematology); Director, Center of Molecular and Cellular Oncology

Mechanisms of B-cell selection as therapeutic targets

Needs: The introduction of inhibitors of BCR signaling have significantly improved outcomes for patients with B-cell malignancies. However, in most cases, patients eventually relapse and some B-cell malignancies are still incurable.

Objectives: Describe mechanisms of central B-cell tolerance and their function in removing autoreactive B-cell clones from the antibody repertoire and how these mechanisms function to remove premalignant B cells and fully transformed B-cell leukemia and lymphoma cells.

Please use this URL to join:
https://ynhh.zoom.us/j/95315328906?pwd=dHh5MjNzU1hEb25pN3lmMGFram9GQT09
Password: 573736 Or join by phone: +1 301 715 8592